Beam Therapeutics grants 80,000 stock options

Beam Therapeutics Inc. reported an insider equity award for its President, Giuseppe Ciaramella.

Accepted by SEC EDGAR 02/02/2026 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Beam Therapeutics Inc. reported an insider equity award for its President, Giuseppe Ciaramella. On January 31, 2026, he received a stock option to buy 80,000 shares of common stock at an exercise price of $27.62 per share.

The option was granted directly to him and is scheduled to vest in equal monthly installments over 48 months following the grant date. Each vesting installment is conditioned on his continued service with Beam Therapeutics through the applicable vesting date.

Insider Trade Summary

Grant/Award: 80,000 shares

Grant/Award 1 txn

Insider Ciaramella Giuseppe

Role President

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	80,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 80,000 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 80,000 contracts (Direct)

Footnotes (1)

1. F1. This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Beam Therapeutics (BEAM) report for Giuseppe Ciaramella?

Beam Therapeutics reported a stock option grant to President Giuseppe Ciaramella. He received options to purchase 80,000 shares of common stock at an exercise price of $27.62 per share, recorded as a direct holding, under a standard multi-year vesting schedule.

How many Beam Therapeutics (BEAM) shares are covered by the new stock option?

The new stock option covers 80,000 shares of Beam Therapeutics common stock. These shares are not owned outright today; they become purchasable over time as the option vests, provided Giuseppe Ciaramella continues his service with the company throughout the vesting period.

What is the exercise price of Giuseppe Ciaramella’s Beam Therapeutics stock option?

The exercise price of the stock option is $27.62 per share. This is the fixed price at which Ciaramella may purchase Beam Therapeutics common stock as portions of the 80,000-share option vest over the 48-month vesting schedule described in the filing.

How does the 80,000-share Beam Therapeutics option vest over time?

The 80,000-share stock option vests in equal monthly installments over 48 months after the January 31, 2026 grant date. Each month, a portion becomes exercisable, but only if Giuseppe Ciaramella remains in continuous service with Beam through each corresponding vesting date.

When does the Beam Therapeutics stock option granted to Giuseppe Ciaramella expire?

The stock option granted to Giuseppe Ciaramella expires on January 31, 2036. Until that expiration date, vested portions of the option may be exercised at the $27.62 per-share exercise price, subject to the monthly vesting conditions and his continued service with Beam Therapeutics.

Is Giuseppe Ciaramella’s Beam Therapeutics stock option held directly or indirectly?

The filing shows the 80,000-share stock option as held directly by Giuseppe Ciaramella. There is no indication of an intermediary entity such as a trust or partnership, and the nature of ownership field does not list any indirect ownership arrangement for this derivative security.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ciaramella Giuseppe

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.62	01/31/2026		A		80,000		(1)	01/31/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.